Gemcitabine-iDRS did not show superior bladder-intact event-free survival over chemoradiotherapy and there were no patient subgroups that suggest further evaluation in subsequent studies.
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will provide further exploratory and post-hoc subgroup analysis data focusing on ...
Inhaled seralutinib demonstrated clinical activity in high-risk pulmonary arterial hypertension patients despite missing its primary phase 3 endpoint.
In a subgroup analysis of people living with HIV enrolled in PRIOH-1, pritelivir demonstrated superior lesion healing, achieving 61% complete ...
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver ...
The MarketWatch News Department was not involved in the creation of this content. EORTC QLQ-C30 subgroup results confirm broad and durable quality-of-life improvements across disease stages and ...
A phase 2 study using metronomic gemcitabine, doxorubicin, and docetaxel plus nivolumab in advanced leiomyosarcoma and liposarcoma (NCT04535713). The broad-spectrum KIT inhibitor NB003 and activity in ...
Objective To evaluate sex differences in perioperative characteristics, in-hospital outcomes and long-term survival following ...
Results presented at the American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO GU 2025) Treatment with UGN-102 resulted in durable complete response (CR) rates across subgroups ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results